Teva Pharmaceutical Industries Limited [NYSE: TEVA] stock went down by -0.10% or -0.01 points down from its previous closing price of $10.25. The stock reached $10.24 during the last trading session. During the course of the last 5 trading session in the week, TEVA share price went up during 2 out of 5 days, that way N/A unch in the period of the last 7 days.
TEVA had two major price movements with the latest trading session as the price jumped to a high of $10.58, at one point touching $10.17. The latest high is set lower that the high price recorded in the period of the last 52 weeks, set at $10.58. The 52-week high currently stands at $22.29 distance from the present share price, noting recovery -52.92% after the recent low of $6.07.
Teva Pharmaceutical Industries Limited [NYSE:TEVA]: Analyst Rating and Earnings
Its stock price has been found in the range of 6.07 to 22.29. This is compared to its latest closing price of $10.25.
Keep looking out for the next-scheduled quarterly financial results that this company is expected to put out, which is slated to occur on Coming Soon.. ).
Fundamental Analysis of Teva Pharmaceutical Industries Limited [TEVA]
Now let’s turn to look at profitability: with a current Operating Margin for Teva Pharmaceutical Industries Limited [TEVA] sitting at +15.22 and its Gross Margin at +44.00, this company’s Net Margin is now -23.20%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is 5.98, and its Return on Invested Capital has reached -3.20%. Its Return on Equity is -13.42, and its Return on Assets is -3.28. These metrics suggest that this Teva Pharmaceutical Industries Limited does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Teva Pharmaceutical Industries Limited [TEVA] has generated a Total Debt to Total Equity ratio of 196.61. Similarly, its Total Debt to Total Capital is 66.29, while its Total Debt to Total Assets stands at 47.65. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 2.71, and its Long-Term Debt to Total Capital is 181.55.
What about valuation? This company’s Enterprise Value to EBITDA is 8.14 and its Total Debt to EBITDA Value is 6.38. The Enterprise Value to Sales for this firm is now 2.18, and its Total Debt to Enterprise Value stands at 0.65. Teva Pharmaceutical Industries Limited [TEVA] has a Price to Book Ratio of 1.16, a Price to Cash Flow Ratio of 3.98.
Shifting the focus to workforce efficiency, Teva Pharmaceutical Industries Limited [TEVA] earns $1,593,631 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 2.92 and its Total Asset Turnover is 0.29. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.63 and its Current Ratio is 0.96. This company is not investing its short-term assets in an optimally efficient way, making it a riskier investment.
Teva Pharmaceutical Industries Limited [TEVA] has 1.09B shares outstanding, amounting to a total market cap of $11.19B. Its stock price has been found in the range of 6.07 to 22.29. At its current price, it has moved down by -54.06% from its 52-week high, and it has moved up 68.70% from its 52-week low.
This stock’s Beta value is currently 1.77, which indicates that it is 5.30% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 69.48. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Teva Pharmaceutical Industries Limited [TEVA] a Reliable Buy?
Teva Pharmaceutical Industries Limited [TEVA] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.